12:00 AM
Feb 11, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lysine-specific demethylase 3A (KDM3A; JMJD1A)


INDICATION: Multiple myeloma (MM)

Patient sample, cell culture and mouse studies suggest inhibiting KDM3A could help treat multiple myeloma (MM). In patients, MM cells had higher levels of KDM3A than normal plasma...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >